Personalised medicine for brain tumour patients: from basic research to preclinical models

The purpose is to enlarge our portfolio of brain tumour organoids and animal models, which will allow us to assess drug responses in molecularly defined groups of tumours in the personal medicine regiments. We plan to advance our models by incorporating human immune system to the organoid cultures and immunodeficient mice. This will allow us to test novel treatment options including immunotherapies and viral-based treatments.

Participation conditions

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all the following criteria:

1.     Patient diagnosed with suspected nervous system tumour

2.     Patient scheduled for surgical resection or biopsy

3.     Provision of signed and dated informed consent form

Exclusion criteria

An individual who meets any of the following criteria will be excluded from participation in this study: Known prion or viral active infections, including but not limited to HIV, Hepatitis A/B/C and CMV.

Screen Failures

The patient will be withdrawn from the study if:

1.     Limited amount of tissue was collected during surgical resection or biopsy. In case of limited surgical resection, the entire tissue is transferred to LNS for the diagnosis.

2.     In case of emergency tumour resection, which can occur with a diagnosed malignant brain tumour, when the patient is not in state to understand and sign the Informed Consent Form: The neurosurgical waste will be kept until the study can be explained to the patient or his / her legal representative and the informed consent is signed. The freshness of the tissue is crucial for the experiments hence while waiting for the patient’s answer, the tissue will be processed and the remaining tissue will be snap-frozen. If not consent is obtained, the cell cultures and the frozen tissue will be discarded. Patient data and blood sample will only be collected after the Informed consent Form has been signed by the participant.

CHL Centre Hospitalier de Luxembourg